Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUF0BJ)

• Drug Name: CYTISINE Drug Info
• Synonyms: CYTISINE; 485-35-8; Sophorine; Baptitoxine; (-)-Cytisine; Laburnin; Baptitoxin; Tabex; Ulexin; Cytiton; Ulexine; Tsitizin; Cytitone; Cystisine; Cytizin; Citizin; Tabax; (1R,5S)-3,4,5,6-Tetrahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-8(2H)-one; Baphitoxine; UNII-53S5U404NU; Cytisine (-); HSDB 3560; EINECS 207-616-0; NSC 407282; BRN 0083882; Cytisin; (1r,5s)-1,2,3,4,5,6-Hexahydro-8h-1,5-Methanopyrido[1,2-A][1,5]diazocin-8-One; CHEBI:4055; CHEMBL497939; 53S5U404NU; Cytisine, 98%

Indication

Disease Entry	ICD 11	Status	REF
Tobacco dependence	6C4A.2	Phase 3	[1]

• Cross-matching ID:
  PubChem CID: 10235
  ChEBI ID: CHEBI:4055
  CAS Number: CAS 485-35-8
  TTD Drug ID: DMUF0BJ

Molecule-Related Drug Atlas

Drug(s) Targeting Neuronal acetylcholine receptor alpha-7 (CHRNA7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ziprasidone	DMM58JY	Bipolar disorder	6A60	Approved	[7]
ALCURONIUM	DM2U4XQ	Anaesthesia	9A78.6	Approved	[8]
AMG 386	DMQJXL4	Breast cancer	2C60-2C65	Phase 3	[9]
EVP-6124	DMLQO7F	Alzheimer disease	8A20	Phase 3	[10]
GTS-21	DMEN5KA	Parkinson disease	8A00.0	Phase 2	[11]
JNJ-39393406	DMUOEKM	Depression	6A70-6A7Z	Phase 2	[12]
ABT-126	DM2OS51	Alzheimer disease	8A20	Phase 2	[13]
TC-6987	DMNFP21	Asthma	CA23	Phase 2	[14]
AQW-051	DMD2RFO	Alzheimer disease	8A20	Phase 2	[15]
MEM-3454	DMPNDYU	Schizophrenia	6A20	Phase 2	[7]

Drug(s) Targeting Neuronal acetylcholine receptor alpha-2 (CHRNA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rocuronium	DMY9BMK	Muscle spasm	MB47.3	Approved	[16]
Tubocurarine	DMBZIVP	Anaesthesia	9A78.6	Approved	[16]
Cisatracurium	DMUZPJ5	Muscle spasm	MB47.3	Approved	[16]
Vecuronium	DMP0UK2	Spasm	MB47.3	Approved	[16]
Levallorphan	DMCOLUP	Narcotic depression	6A7Z	Approved	[17]
Mivacurium	DM473VD	Anaesthesia	9A78.6	Approved	[16]
Carbachol	DMX9K8F	Glaucoma/ocular hypertension	9C61	Approved	[17]
Pipecuronium	DM5F84A	Spasm	MB47.3	Approved	[17]
CHOLINE	DM5D9YK	Insomnia	7A00-7A0Z	Investigative	[18]
[125I]epibatidine	DMZWQH3	Discovery agent	N.A.	Investigative	[19]

Drug(s) Targeting Neuronal acetylcholine receptor alpha-4 (CHRNA4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trimethaphan	DMHF4IQ	Aneurysm	BD51.Z	Approved	[20]
Pentolinium	DM38VYQ	Hypotension	BA20-BA21	Approved	[21]
ABT-594	DMGMBCW	N. A.	N. A.	Discontinued in Phase 2	[22]
ABT-418	DMNP72I	Alzheimer disease	8A20	Discontinued in Phase 2	[23]
HOMOEPIBATIDINE	DMHP9WV	N. A.	N. A.	Terminated	[3]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	DMM9X0G	Discovery agent	N.A.	Investigative	[24]
Barbituric acid derivative	DM2I19P	Discovery agent	N.A.	Investigative	[25]
(2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol	DMDUGZS	Discovery agent	N.A.	Investigative	[26]
(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol	DMDUI8R	Discovery agent	N.A.	Investigative	[26]
BOLDINE	DMMVB5P	Discovery agent	N.A.	Investigative	[27]

Drug(s) Targeting Neuronal acetylcholine receptor beta-4 (CHRNB4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SIB-1553A	DM7XC0U	Alzheimer disease	8A20	Discontinued in Phase 2	[28]
HOMOEPIBATIDINE	DMHP9WV	N. A.	N. A.	Terminated	[3]
(2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol	DMDUGZS	Discovery agent	N.A.	Investigative	[26]
(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol	DMDUI8R	Discovery agent	N.A.	Investigative	[26]
GCCSNPVCHLEHSNLC*	DMJ0ICN	Discovery agent	N.A.	Investigative	[29]
18-Methylaminocoronaridine	DMOYC0U	Discovery agent	N.A.	Investigative	[30]
15-nor-18-Methoxycornaridine	DMDKFGX	Discovery agent	N.A.	Investigative	[30]
2-Acetylaminoethyl 18-methoxycoronaridinate	DM9ZOX4	Discovery agent	N.A.	Investigative	[30]
N,N-Dimethylaminoethyl 18-methoxycoronaridinate	DMWJ2PM	Discovery agent	N.A.	Investigative	[30]
2-Methoxyethyl 18-methoxycoronaridinate	DM6X8GN	Discovery agent	N.A.	Investigative	[30]

Drug(s) Targeting Nicotinic acetylcholine receptor (nAChR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[31]
Cotinine	DMCEZ1B	Insecticide	N.A.	Approved	[32]
Pancuronium	DMB0VY8	Anaesthesia	9A78.6	Approved	[16]
Atracurium	DM42HXN	Anaesthesia	9A78.6	Approved	[16]
Mecamylamine	DMGQFYB	Essential hypertension	BA00	Approved	[33]
Dexefaroxan	DMTY4KN	Parkinson disease	8A00.0	Phase 2	[7]
BMS-954561	DM7XV4R	Diabetic neuropathy	8C0Z	Phase 2	[34]
ASM-024	DM35S2I	Asthma	CA23	Phase 2	[35]
NIC-002	DMKLJMI	Nicotine dependence	6C4A.2	Phase 2	[36]
TRIDMAC	DMWU41P	Mood disorder	6A60-6E23	Phase 2	[37]

Drug(s) Targeting Neuronal acetylcholine receptor beta-2 (CHRNB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TC-5214	DM8AM60	Palmar hyperhidrosis	EE00.00	Phase 2	[38]
SUVN-911	DMLPBVF	Major depressive disorder	6A70.3	Phase 1	[1]
AZD-9684	DMHA5ME	Thrombosis	DB61-GB90	Discontinued in Phase 2	[39]
ABT-594	DMGMBCW	N. A.	N. A.	Discontinued in Phase 2	[22]
ABT-418	DMNP72I	Alzheimer disease	8A20	Discontinued in Phase 2	[40]
HOMOEPIBATIDINE	DMHP9WV	N. A.	N. A.	Terminated	[3]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	DMM9X0G	Discovery agent	N.A.	Investigative	[24]
(2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol	DMDUGZS	Discovery agent	N.A.	Investigative	[26]
(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol	DMDUI8R	Discovery agent	N.A.	Investigative	[26]
BOLDINE	DMMVB5P	Discovery agent	N.A.	Investigative	[27]

Drug(s) Affected By Neuronal acetylcholine receptor subunit alpha-4 (CHRNA4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[41]
Selenium	DM25CGV	N. A.	N. A.	Approved	[42]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Atropine	DMEN6X7	Organophosphate poisoning	NE6Z	Approved	[44]
Galantamine	DMEO794	Alzheimer disease	8A20	Approved	[44]
Rivastigmine	DMG629M	Alzheimer disease	8A20	Approved	[44]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[45]
Scopolamine	DMOM8AL	Addictive disorder	6C50-6C5Z	Approved	[44]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[46]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[47]

Drug(s) Affected By Neuronal acetylcholine receptor subunit beta-2 (CHRNB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[48]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[43]
Atropine	DMEN6X7	Organophosphate poisoning	NE6Z	Approved	[44]
Galantamine	DMEO794	Alzheimer disease	8A20	Approved	[44]
Rivastigmine	DMG629M	Alzheimer disease	8A20	Approved	[44]
Scopolamine	DMOM8AL	Addictive disorder	6C50-6C5Z	Approved	[44]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[49]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[50]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[51]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[52]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Neuronal acetylcholine receptor alpha-2 (CHRNA2)	TTF4E0J	ACHA2_HUMAN	Inhibitor	[2]
Neuronal acetylcholine receptor alpha-4 (CHRNA4)	TT4H1MQ	ACHA4_HUMAN	Inhibitor	[3]
Neuronal acetylcholine receptor alpha-7 (CHRNA7)	TTLA931	ACHA7_HUMAN	Inhibitor	[4]
Neuronal acetylcholine receptor beta-2 (CHRNB2)	TT5KPZR	ACHB2_HUMAN	Inhibitor	[3]
Neuronal acetylcholine receptor beta-4 (CHRNB4)	TTTVAFQ	ACHB4_HUMAN	Inhibitor	[5]
Nicotinic acetylcholine receptor (nAChR)	TTJSZTB	NOUNIPROTAC	Antagonist	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Neuronal acetylcholine receptor subunit alpha-4 (CHRNA4)	OT1H0ZXC	ACHA4_HUMAN	Protein Interaction/Cellular Processes	[6]
Neuronal acetylcholine receptor subunit beta-2 (CHRNB2)	OTNAT2M5	ACHB2_HUMAN	Protein Interaction/Cellular Processes	[6]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity. J Med Chem. 2006 May 4;49(9):2673-6.
• [3] Epibatidine isomers and analogues: structure-activity relationships. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5493-7.
• [4] 3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation. Bioorg Med Chem Lett. 2005 Nov 15;15(22):4889-97.
• [5] Deconstructing cytisine: The syntheses of (+/-)-cyfusine and (+/-)-cyclopropylcyfusine, fused ring analogs of cytisine. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2316-9.
• [6] ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties. J Pharmacol Exp Ther. 1997 Oct;283(1):235-46.
• [7] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [8] Pharmacological characteristics and binding modes of caracurine V analogues and related compounds at the neuronal alpha7 nicotinic acetylcholine re... J Med Chem. 2007 Sep 20;50(19):4616-29.
• [9] Clinical pipeline report, company report or official report of Roche (2009).
• [10] Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract. 2014 Jan;20(1):12-24.
• [11] The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res. 2000 Aug;113(1-2):169-81.
• [12] Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology. 2013 Jan;64:197-204.
• [13] A phase 2 randomized, controlled trial of the alpha7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia. Alzheimer's & Dementia: Translational Research & Clinical Interventions Volume 1, Issue 1, June 2015, Pages 81-90.
• [14] ClinicalTrials.gov (NCT01293669) Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
• [15] AQW051, a novel and selective nicotinic acetylcholine receptor alpha7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys. Parkinsonism Relat Disord. 2014 Nov;20(11):1119-23.
• [16] Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.
• [17] Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33.
• [18] Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1845-8.
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 463).
• [20] Mechanism of long-lasting block of ganglion nicotinic receptors by mono-ammonium compounds with long aliphatic chain. J Auton Nerv Syst. 1994 Aug;48(3):231-40.
• [21] Nicotinic and nonnicotinic receptor-mediated actions of vinblastine. Proc Soc Exp Biol Med. 1993 Jul;203(3):372-6.
• [22] The nicotinic acetylcholine receptor agonist ABT-594 increases FGF-2 expression in various rat brain regions. Neuroreport. 1999 Dec 16;10(18):3909-13.
• [23] (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization. J Pharmacol Exp Ther. 1994 Jul;270(1):319-28.
• [24] Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
• [25] Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57.
• [26] Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48.
• [27] Aporphine metho salts as neuronal nicotinic acetylcholine receptor blockers. Bioorg Med Chem. 2007 May 15;15(10):3368-72.
• [28] SIB-1553A, (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride, a subtype-selective ligand for nicotinic acetylcholine receptors with putative cognitive-enhancing properties: effectson working and reference memory performances in aged rodents and nonhuman primates. J Pharmacol Exp Ther. 2001 Oct;299(1):297-306.
• [29] Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J Med Chem. 2005 Jul 28;48(15):4705-45.
• [30] Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J Med Chem. 2003 Jun 19;46(13):2716-30.
• [31] Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptors. Neuropharmacology. 2009 Aug;57(2):183-91.
• [32] Functional versus chemical diversity: is biodiversity important for drug discovery. Trends Pharmacol Sci. 2002 May;23(5):225-31.
• [33] Mecamylamine (Inversine): an old antihypertensive with new research directions. J Hum Hypertens. 2002 Jul;16(7):453-7.
• [34] EP patent application no. 2774991, Drug delivery system for use in the treatment or diagnosis of neurological disorders.
• [35] Effects of ASM-024, a modulator of acetylcholine receptor function, on airway responsiveness and allergen-induced responses in patients with mild asthma. Can Respir J. 2015 Jul-Aug;22(4):230-4.
• [36] Therapeutic advances in the treatment of nicotine addiction: present and future. Ther Adv Chronic Dis. 2010 May; 1(3): 95-106.
• [37] Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
• [38] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [39] Blockade and activation of the human neuronal nicotinic acetylcholine receptors by atracurium and laudanosine. Anesthesiology. 2001 Apr;94(4):643-51.
• [40] Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch Med Res. 2000 Mar-Apr;31(2):131-44.
• [41] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [42] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [43] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [44] Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism. Eur J Pharmacol. 2005 Feb 21;509(2-3):97-108. doi: 10.1016/j.ejphar.2004.12.037.
• [45] Rosiglitazone inhibits alpha4 nicotinic acetylcholine receptor expression in human lung carcinoma cells through peroxisome proliferator-activated receptor gamma-independent signals. Mol Cancer Ther. 2009 Jan;8(1):110-8. doi: 10.1158/1535-7163.MCT-08-0719.
• [46] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [47] The C terminus of the human nicotinic alpha4beta2 receptor forms a binding site required for potentiation by an estrogenic steroid. J Neurosci. 2001 Sep 1;21(17):6561-8. doi: 10.1523/JNEUROSCI.21-17-06561.2001.
• [48] Cyclosporine A--induced oxidative stress in human renal mesangial cells: a role for ERK 1/2 MAPK signaling. Toxicol Sci. 2012 Mar;126(1):101-13.
• [49] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [50] Repetitive nicotine exposure leads to a more malignant and metastasis-prone phenotype of SCLC: a molecular insight into the importance of quitting smoking during treatment. Toxicol Sci. 2010 Aug;116(2):467-76. doi: 10.1093/toxsci/kfq138. Epub 2010 May 10.
• [51] Molecular modelling of the interactions of carbamazepine and a nicotinic receptor involved in the autosomal dominant nocturnal frontal lobe epilepsy. Br J Pharmacol. 2002 Jul;136(6):883-95. doi: 10.1038/sj.bjp.0704786.
• [52] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.